Renal denervation for hypertension
Cardiovascular therapies and procedures
The Symplicity™ blood pressure procedure provides a
complementary approach to hypertension (HTN) treatment.
Transforming hypertension treatment
adults with hypertension worldwide1
of hypertension patients do not have their blood pressure under control1
of hypertension patients become non-adherent to their medication within one year2
Hypertension is a leading preventable cause of heart attack, stroke, and death.3 But medication and lifestyle modifications are not always enough to control it.
A novel approach to treating hypertension
The Symplicity blood pressure procedure complements medication and lifestyle changes to treat hypertension. But unlike medications, it maintains blood pressure (BP) reductions over a 24-hour period.4-6
See how the Symplicity Spyral™ system works
The Symplicity Spyral™ renal denervation system supplies precisely controlled and targeted radiofrequency (RF) energy to the renal nerves, safely disrupting the overactive sympathetic signaling between the kidneys and brain to reduce blood pressure.7
Proven to reduce blood pressure4
The Symplicity blood pressure procedure is proven to achieve safe and clinically meaningful blood pressure reduction in the presence and absence of medications in multiple clinical trials and a real-world patient registry.4-6,8
Imagine the impact
Key findings from the GLOBAL SYMPLICITY REGISTRY found a 26% reduction in Major Adverse Cardiovascular Events (MACE) risk with the Symplicity blood pressure procedure compared to a modeled control group.9
Take action on HTN
Gain access to resources to introduce the Symplicity blood pressure procedure to your community successfully.
Start referring patients
See how the Symplicity blood pressure procedure can enhance your hypertension treatment strategies as a complementary approach.
Learn more about Symplicity
Explore CME courses, peer presentations, training materials, and other educational content about the Symplicity procedure.
*
In typical uncontrolled hypertension patients.
†
ANCOVA adjusted; secondary efficacy analysis.
‡
RDN arm reduction from baseline.
§
Compared to modeled control group in the GLOBAL SYMPLICITY REGISTRY.
1
World Health Organization. Hypertension fact sheet. https://www.who.int/news-room/fact sheets/detail/hypertension. Published August 25, 2021. Accessed November 3, 2021.
2
Jung O, Gechter JL, Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. Hypertension. 2013;31(4):766-774
3
Bundy JD, Li C, Stuchlik P, et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality. JAMA Cardiology. 2017:1;2(7):775–781.
4
Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. The Lancet. 2020;395:1444–1451
5
Mahfoud F, Kandzari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. The Lancet. 2022; 399:1401-1410.
6
Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. The Lancet. 2020;395:1444–1451.
7
Coates P, Tunev S, Trudel J, et al. Time, temperature, power, and impedance considerations for radiofrequency catheter renal denervation. Cardiovascular Revascularization Medicine. 2022.
8
Mahfoud F, Mancia G, Schmieder R, et al. Three-year safety and efficacy in the Global Symplicity Registry: Impact of antihypertensive medication burden on blood pressure reduction. Presented at PCR e-course 2020.
9
Schmieder R, Böhm M, Schlaich M, et al. Modeled Clinical Event Reductions at Three Years in High-Risk Hypertension Patients Treated with Renal Denervation. Presented at Deutsche Gesellschaft fur Kardiologie 2021.